Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Intraperitoneal Paclitaxel-loaded TPM for Peritoneal Carcinomatosis
NCT05159050Phase 1Terminated
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in peritoneal carcinomatosis (PC). Primary endpoints: Safety of intraperitoneal Paclitaxel-loaded TPM at 12 weeks and Maximum Tolerated Dose at 4 weeks. Started Apr 2022; status: terminated.
02
Drugs
paclitaxel
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT05159050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159050.